Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, Viking Therapeutics Inc increased its cash reserves by 51.55%, or 18.88m. Cash Flow from Financing totalled 271.38m or -- of revenues. In addition the company used 73.38m for operations while cash used for investing totalled 179.09m.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 8.18 |
---|---|
Tangible book value per share | 8.18 |
More ▼
Balance sheet in USDView more
Current ratio | 36.47 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼